Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Autolus Therapeutics (AUTL – Research Report) and Abiomed (ABMD – Research Report). Autolus Therapeutics (AUTL) In a report released today, Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics, with a price target of $12.00. The company's shares closed last Thursday at $3.12. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-autolus-therapeutics-autl-and-abiomed-abmd?utm_source=advfn.com&utm_medium=referral
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Autolus Therapeutics Charts.
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Autolus Therapeutics Charts.